Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drug-induced tardive dyskinesia.

H Itoh

    Current Developments in Psychopharmacology
    |January 1, 1981
    PubMed
    Summary

    Tardive dyskinesia is a persistent side effect of long-term psychotropic drug use. Early diagnosis and drug removal are crucial for managing this condition, as effective treatments remain elusive.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    A case of protracted suffocation death.

    Nihon hoigaku zasshi = The Japanese journal of legal medicine·1992
    Same author

    [CT diagnosis of diffuse lung disease].

    Nihon Kyobu Shikkan Gakkai zasshi·1992
    Same author

    Extracellular matrix formation in piecemeal necrosis: immunoelectron microscopic study.

    Liver·1992
    Same author

    Listeric septicemia with meningitis in a neonatal calf.

    The Journal of veterinary medical science·1992
    Same author

    [Exercise therapy on the basis of anaerobic threshold (AT)].

    Kokyu to junkan. Respiration & circulation·1992
    Same author

    [Molecular biology of the natriuretic peptide system].

    Nihon rinsho. Japanese journal of clinical medicine·1992

    Area of Science:

    • Neuroscience
    • Psychiatry
    • Pharmacology

    Background:

    • Tardive dyskinesia (TD) is a neurological disorder associated with long-term use of psychotropic medications, particularly neuroleptics.
    • Reported since the 1950s, TD can persist for years even after medication cessation.
    • Prevalence varies globally, affecting 10-30% of psychiatric patients in Europe/North America and 5-20% in Japan.

    Purpose of the Study:

    • To review the symptomatology, etiology, diagnosis, prognosis, and management of drug-induced tardive dyskinesia.
    • To present findings from cross-national surveys and studies on TD reversibility.
    • To highlight the challenges in treating tardive dyskinesia and emphasize preventive strategies.

    Main Methods:

    • Review of existing literature and investigations on tardive dyskinesia.
    • Cross-national survey data analysis.
    • Studies on the reversibility of tardive dyskinesia symptoms.

    Main Results:

    • Tardive dyskinesia affects a significant percentage of long-term psychiatric patients.
    • Despite numerous investigations into its biochemical etiology, no consistently successful therapies have been identified.
    • Some studies indicate potential reversibility of symptoms under certain conditions.

    Conclusions:

    • Early diagnosis of dyskinetic symptoms is critical for effective management.
    • Removal of the causative psychotropic drugs is a key intervention.
    • Preventive care and vigilant monitoring during psychotropic drug treatment are essential to mitigate the risk and impact of tardive dyskinesia.

    Related Experiment Videos